Whether the peptide is a neoantigen that can be targeted on AML by immunotherapy, for example by T cells engineered with TCRs of our RUNX1-specific clones, requires further testing of T cell clones against HLA-DQB1*03:02 positive patient-derived AML samples carrying RUNX1 frameshift mutations, which were not available in our biobank and could not be easily collected. The gene discussed is RUNX1; the disease is acute myeloid leukemia.